January 17th 2025
Production is set to take place at Samsung Biologics’ Songdo, South Korea, site, and the agreement will run through December 2030, subject to change.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
The current and future market for SNPs
April 1st 2010Single nucleotide polymorphisms (SNPs) are responsible for more than 80% of the variations between individuals, and are present throughout most genes and other important sequences in the human body, which makes them ideal for tracking down correlations between genotype and phenotype.
Future research strategies for glucocorticoid therapy
April 1st 2010Why do some people contact diseases while others stay healthy? This is a central question in medicine. Similarly, why some individuals recover quickly using drug treatments while others do not is a fundamental question in pharmacology.
Overcoming manufacturing and financial challenges of personalized cell therapies
March 30th 2010Person-specific cell therapy could potentially offer a cure as opposed to ongoing treatment, but it is also a disruptive technology that doesn't currently fit into traditional therapeutic manufacturing processes.
Developing a safe lyophilised adjuvant vaccine
March 12th 2010There are a variety of vaccine types, each varying in safety and efficacy, and each possessing its own formulation challenges. To overcome potential instabilities when developing vaccines, one formulation strategy is to produce a dried product.
Measuring headspace gas concentrations and residual moisture content
March 12th 2010Technological advances and regulatory documents, such as Annex 1 of the EU Guideline for Good Manufacturing Practice, have encouraged the pharmaceutical industry to install various new technologies into their production lines.